Holen Sie sich die Stockscreener-App
1.81
5.85%
0.10
Handel nachbörslich:
1.89
0.08
+4.42%
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
PROQR THERAPEUTICS NV PB Ratio: 3.11 — Near Median - GuruFocus
If You Invested $1,000 in Proqr Therapeuti (PRQR) - stocktitan.net
Analysts Set $6.80 Price Target for ProQR Therapeutics - National Today
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
What analysts say about ProQR Therapeutics NV stockWeekly Trend Recap & Expert Verified Movement Alerts - baoquankhu1.vn
US Market Recap: Can ProQR Therapeutics NV benefit from deglobalization2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Aug Reactions: Can ProQR Therapeutics NV weather a recessionMarket Growth Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn
PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Retail Trends: Will ProQR Therapeutics NV stock recover after earningsIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - The Globe and Mail
Price Action: Is ProQR Therapeutics NV attractive for institutional investors2026 Pullback Review & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance
ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 - GlobeNewswire
Ahead of AX-0810 data, ProQR plans April 8 pipeline webcast - stocktitan.net
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN
Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World
ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan
ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan
Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan
ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan
ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan
Theresa Heggie (PRQR) details option and share holdings in Form 3 - Stock Titan
ProQR Therapeutics N.V. (PRQR) director files Form 3 for options - Stock Titan
ProQR (PRQR) CEO Daniel de Boer details long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director reports five long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director discloses share and option holdings - Stock Titan
Q2 Earnings Estimate for PRQR Issued By HC Wainwright - MarketBeat
Brokers Issue Forecasts for PRQR Q1 Earnings - MarketBeat
Aug Sentiment: Whats the RSI of ProQR Therapeutics NV stock2026 Highlights & Low Risk Profit Maximizing Plans - baoquankhu1.vn
ProQR Therapeutics N.V.Ordinary Shares (NQ: PRQR - The Chronicle-Journal
Recap Report: Is ProQR Therapeutics NV a strong candidate for buy and hold2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Breakout Zone: Is ProQR Therapeutics NV attractive for institutional investors2026 Opening Moves & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates By Investing.com - Investing.com Australia
ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen - Defense World
ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citizens reiterates ProQR Therapeutics stock rating on RNA editing platform potential - Investing.com
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer - MarketBeat
ProQR Therapeutics Q4 2025 Financial Results: Loss of $9.1MNews and Statistics - IndexBox
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
ProQR: Q4 Earnings Snapshot - marketscreener.com
ProQR Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027 - TipRanks
ProQR (PRQR) Advances Clinical Trials Amid Reduced Cash Holdings - GuruFocus
ProQR Therapeutics (NASDAQ: PRQR) details 2025 loss, cash runway and RNA editing focus - Stock Titan
ProQR Announces Year End 2025 Operating and Financial Results - weeklyvoice.com
ProQR (Nasdaq: PRQR) widens 2025 loss as R&D spending rises - Stock Titan
ProQR: Fourth Quarter Financial Overview - Bitget
Analysts Set ProQR Therapeutics Price Target at $7.14 - National Today
ProQR Therapeutics NV expected to post a loss of 10 cents a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quarterly Risk: Can ProQR Therapeutics NV weather a recession2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Weekly Trades: Is ProQR Therapeutics NV backed by strong institutional buyingJuly 2025 Pullbacks & Verified Momentum Stock Alerts - baoquankhu1.vn
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):